The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1084/jem.20091507
The Journal of Experimental Medicine, Vol. 206, No. 8, 1647-1651
The Rockefeller University Press, 0022-1007 $30.00
© Bolland et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1378K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Bolland, S.
Right arrow Articles by Garcia-Sastre, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolland, S.
Right arrow Articles by Garcia-Sastre, A.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

 Vicious circle: systemic autoreactivity in Ro52/TRIM21-deficient mice

Silvia Bolland and Adolfo Garcia-Sastre

S. Bolland is at Laboratory of Immunogenetics, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville MD 20852. A. Garcia-Sastre is at the Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029

CORRESPONDENCE S.B.: SBolland{at}niaid.nih.gov


ABSTRACT
Dysregulated innate responses, particularly excessive activation of interferon (IFN) pathways, have been implicated in the development of autoimmune pathologies. Autoreactivity frequently targets IFN-inducible genes such as the Ro autoantigens, which ubiquitinate and inhibit interferon regulatory factors (IRFs). A new study validates the role of these common autoantigens in preventing autoimmunity. The findings reveal that injury-induced systemic autoimmune disease is exacerbated in the absence of Ro52/Trim21 and is driven by the IL-23–Th17 pathway.

© 2009 The Rockefeller University Press
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathway
Alexander Espinosa, Valerie Dardalhon, Susanna Brauner, Aurelie Ambrosi, Rowan Higgs, Fransisco J. Quintana, Maria Sjöstrand, Maija-Leena Eloranta, Joan Ní Gabhann, Ola Winqvist, Birgitta Sundelin, Caroline A. Jefferies, Björn Rozell, Vijay K. Kuchroo, and Marie Wahren-Herlenius
J. Exp. Med. 2009 206: 1661-1671. [Abstract] [Full Text] [PDF]





  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS